> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Kodiak Sciences Raises $69 Million As It Heads Toward Retinal Drug Approval Applications
- URL: https://www.bullished.co/kodiak-sciences-raises-69-million-as-it-heads-toward-retinal-drug-approval-applications-b591567d/
- Published: 2026-11-12T21:05:56.000Z
- Updated: 2026-11-12T21:05:56.000Z
- Description: Management expects cash to support operations into 2027, with December results ahead for its treatment of inflammation-related retinal swelling.
- Author: Matteo Parrino
- Tags: SEC Filings, KOD, Industry: Healthcare

[Kodiak Sciences](https://www.bullished.co/tag/kod/), which develops medicines for retinal diseases, raised [$69 million](https://www.sec.gov/Archives/edgar/data/0001468748/000119312526458248/kod-ex99%5F1.htm?ref=bullished.co) from stock sales after quarter-end as it works toward drug approval applications. In its earnings release attached to Thursday's [SEC filing](https://www.sec.gov/Archives/edgar/data/0001468748/000119312526458248/kod-20261112.htm?ref=bullished.co), management said it expects current cash to support operations into 2027.

## New Cash, More Shares

Kodiak held [$88.7 million](https://www.sec.gov/Archives/edgar/data/0001468748/000119312526458248/kod-ex99%5F1.htm?ref=bullished.co) in cash and cash equivalents at the end of September. The subsequent $69 million in net proceeds came through a program that sells common shares into the market.

The third-quarter loss grew to $66.2 million from $61.5 million a year earlier, including non-cash stock compensation of $12.8 million, compared with $14.0 million. Yet the loss per share narrowed to $1.05 from $1.16: average shares outstanding increased to 62,960,644 from 52,859,308.

Kodiak's cash outlook sits alongside a financial warning. The company said its financial condition raises substantial doubt about its ability to continue operating as a going concern.

## Trials And Manufacturing Cost More

Research and development spending reached $58.3 million in the third quarter, versus $50.5 million a year earlier. Kodiak attributed the increase mainly to trial work on its inflammation-related retinal swelling and diabetic macular edema programs, plus manufacturing for late-stage development.

Research costs included $6.7 million in non-cash stock compensation, down from $7.2 million. Administrative spending fell to $8.8 million from $11.9 million, with stock compensation accounting for $6.1 million versus $6.9 million.

Kodiak attributed the rest of the administrative decrease primarily to a one-time, non-cash gain from ending a Palo Alto building lease. In exchange, it received an option to lease another building on the same campus with lease incentives.

## December's Retinal Swelling Readout

Kodiak has no approved products and retains global rights to its drug candidates. Its technology links antibodies with a biopolymer to extend their activity in the eye; its late-stage portfolio includes Zenkuda, tabirafusp-ted, also called KSI-501, and KSI-101.

Chief Executive Officer Victor Perlroth said, "we expect to announce the first Phase 3 KSI-101 results in December." Enrollment is complete for the initial 300-patient group testing the treatment for retinal swelling caused by inflammation.

Kodiak expects to finish enrolling a second pivotal group of 600 patients across its PEAK and PINNACLE late-stage trials in the fourth quarter. Results are anticipated in the second quarter of 2027, when the company also plans a KSI-101 approval application if the results succeed.

Zenkuda and tabirafusp-ted [met their goals](https://www.sec.gov/Archives/edgar/data/0001468748/000119312526403481/d185059dex991.htm?ref=bullished.co) in a pivotal wet age-related macular degeneration trial, Kodiak announced on September 28\. Under retreatment rules requiring retinal dryness, 54% of Zenkuda patients received treatment every six months. Tabirafusp-ted is also being tested in the enrolling ALTO late-stage trial for diabetic macular edema.

Kodiak plans to submit Zenkuda's approval application by year-end, drawing on five successful late-stage studies covering wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Kodiak Sciences Inc. (KOD)](https://www.sec.gov/Archives/edgar/data/0001468748/000119312526458248/kod-20261112.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit kod-ex99\_1.htm — Kodiak Sciences Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001468748/000119312526458248/kod-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [8-K filed 2026-09-28 — Kodiak Sciences Inc. (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0001468748/000119312526403481/d185059dex991.htm?ref=bullished.co) — SEC EDGAR

### More on Kodiak Sciences

- [Kodiak Sciences' DAYBREAK Trial Delivers Win For Both Zenkuda And Tabirafusp-Ted, With FDA Filing Due This Quarter](https://www.bullished.co/kodiak-sciences-daybreak-trial-delivers-win-for-both-zenkuda-and-tabirafusp-ted-with-fda-c939c4fb/)

[All Kodiak Sciences (KOD) coverage →](https://www.bullished.co/tag/kod/)